References
- Cavallo J. The evolution of liquid biopsy in cancer care. The ASCO Post. [ cited 2021 Oct 10]. Available from: https://ascopost.com/issues/october-10-2021/the-evolution-of-liquid-biopsy-in-cancer-care
- White House (US). Remarks by the president in state of the union address [Internet]. Washington (DC): White House (US); [cited 06 Feb 2016]. Available from: https://obamawhitehouse.archives.gov/the-press-office/2015/01/20/remarks-president-state-union-address-january-20-2015.
- Grossman R, Abel B, Angiuoli S, et al. Collaborating to compete: Blood Profiling Atlas in Cancer (BloodPAC) consortium. Clin Pharmacol Ther. 2017;101(5):589–592.
- BLOODPAC. Our community. Available from: https://www.bloodpac.org/our-community
- Friends of Cancer Research. [cited 2022 Jul]. Available from: https://friendsofcancerresearch.org
- Quality Assurance Initiative in Pathology. [cited 2022 Jul]. Available from: https://www.qualityinpathology.com
- Clinical and Laboratory Standards Institute (CLSI). [cited 2022 Jul]. Available from: https://clsi.org
- Febbo PG, Martin A-M, Scher HI, et al. Minimum Technical Data Elements for liquid biopsy data submitted to public databases. Clin Pharmacol Ther. 2020;107(4):730–734.
- Grossman RL, Dry JR, Hanlon SE, et al. BloodPAC data commons for liquid biopsy data. JCO Clin Cancer Inform. 2021;5:(5)479–486.
- Harmonized Terminology Database, Clinical and Laboratory Standards Institute (CLSI). [cited 2022 Jul]. Available from: https://htd.clsi.org
- Godsey JH, Silvestro A, Barrett JC, et al. On behalf of the BloodPAC consortium, generic protocols for the analytical validation of next-generation sequencing-based ctDNA assays: a joint consensus recommendation of the BloodPAC’s analytical variables working group. Clin Chem. 2020 Sep;66(9):1156–1166.
- Martin A-M. Advancing care for patients during & after treatment: molecular residual disease strategic planning group. BLOODPAC Virtual Summit; 2022. https://youtu.be/b8WrlBMT_P4?t=660